Aromatase inhibitor

Anastrozole (Arimidex)

Anastrozole (Arimidex) is a selective non-steroidal aromatase inhibitor with a mean elimination half-life of 50 hours on its US label, indicated for breast cancer in postmenopausal women.1

Strong evidenceGet the app

Level after one dose

Anastrozole (Arimidex) after one dose: 50% at ~2 days, 25% at 4 days, 12.5% at 6 days.

Drawn from the half-life in the app's model, ~2 days. The model's figures

Anastrozole, sold as Arimidex, is a selective non-steroidal aromatase inhibitor, and its US label states that it "significantly lowers serum estradiol concentrations".1 The US label describes aromatase as the enzyme that converts adrenal androgens, primarily androstenedione and testosterone, to estrone and estradiol in postmenopausal women.1

The label's three indications are adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer, and treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen.1 The label adds that patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arimidex.1 The indications in the UK summary of product characteristics, from AstraZeneca UK Limited, are also in postmenopausal women.2

In randomised trials in older men with low or borderline-low testosterone, anastrozole 1 mg a day or 1 mg twice a week raised testosterone and lowered estradiol, and in a one-year placebo-controlled trial it lowered spine bone mineral density compared with placebo.3,4,5 The WADA 2026 Prohibited List names anastrozole among the aromatase inhibitors prohibited at all times.6

In postmenopausal women

In multiple daily dosing trials with 0.5, 1, 3, 5 and 10 mg in postmenopausal women with advanced breast cancer, the US label reports that doses of 1 mg and higher suppressed mean serum estradiol to the lower limit of detection, 3.7 pmol/L.1 At 1 mg, the label states estradiol fell by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing, and that suppression was maintained for up to 6 days after daily dosing stopped.1 The label also states that the effect of Arimidex in premenopausal women with early or advanced breast cancer has not been studied.1 Mauras and colleagues, Journal of Clinical Endocrinology and Metabolism, 2009, in a study of boys with gynecomastia, describe anastrozole as "a potent and selective reversible inhibitor of the aromatase enzyme in females".7

In men

Finkelstein and colleagues, New England Journal of Medicine, 2013, write that more than 80% of circulating estradiol in men is derived from the aromatization of testosterone.8 In the 12 men given anastrozole 1 mg daily for 12 weeks in a trial of 37 men aged 62 to 74 with low or borderline-low testosterone, mean serum estradiol fell from 26 to 17 pg/ml, and Leder and colleagues write that serum estradiol levels "decrease modestly but remain within the normal male range".3

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~2 days
Bioavailability
95%
Typical dose
0.25–1 mg/day
Route
Oral
Time to peak
~2 h
Table 3.1Pharmacokinetics6 rows
ParameterValueNote
Half-life~2 days (48 hours)The app's figure. The US label gives a mean elimination half-life of 50 hours, the UK summary of product characteristics gives a plasma elimination half-life of 40 to 50 hours, and in 42 boys with gynecomastia the terminal half-life was 46.8 hours.1,2,7
Bioavailability (oral)~95%The app's figure. The US label states that orally administered anastrozole is well absorbed into the systemic circulation and gives no percentage, and the UK summary of product characteristics gives none either.1,2
Time to peak~2 hoursThe app's figure. The US label states that maximum plasma concentrations typically occur within 2 hours of dosing under fasted conditions and that food reduces the rate but not the overall extent of absorption, and in the boys' study the time to maximum concentration was 1 hour.1,7
Duration of effect~4 days (96 hours)The app's figure. The US label states that estradiol suppression was maintained for up to 6 days after daily dosing with 1 mg stopped, in postmenopausal women with advanced breast cancer.1
Steady stateAbout 7 days of once daily dosing1Steady-state plasma levels are approximately 3- to 4-fold higher than after a single dose, and the UK summary states that approximately 90 to 95% of steady-state concentrations are attained after 7 daily doses.1,2
RouteOralThe US label describes a 1 mg tablet.1

The US label states that anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer.1 It reports that anastrozole is 40% bound to plasma proteins, that hepatic metabolism accounts for approximately 85% of elimination and renal elimination for approximately 10% of total clearance, and that the major circulating metabolite, triazole, lacks pharmacologic activity.1

The chart below draws a one-compartment model with the app's half-life of 48 hours and time to peak of 2 hours. Its half-life is shorter than the 50 hours on the US label, so its curve falls slightly faster than one drawn from the label.1 The interval choices follow the sources: 1 mg once daily in the US label and the trials, and 1 mg twice weekly in the Leder trial, which the chart spaces evenly at 3.5 days.1,3

Level over 3 weeks

Interval between doses

Level, as a share of the peak after one 1 mg dose

As studied: every day1, twice a week3.

An illustration from a pharmacokinetic model using a half-life of 48 hours (2 days). It is not a measured level or a suggested dose.

4

Human studies

The US label describes the ATAC trial as randomizing 9,366 postmenopausal women with operable breast cancer.1 The randomised trials of anastrozole in older or hypogonadal men in the table below enrolled 26 to 88 men each.9,4 The trial in healthy men by Finkelstein and colleagues enrolled 198 and 202 men in its two cohorts.8

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Howell and colleagues, Lancet, 200510Randomised against tamoxifen; AstraZeneca is the registry's lead sponsor10,119366 postmenopausal women with localised breast cancer10Anastrozole against tamoxifen for 5 years10Disease-free survival events 575 against 651 (hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) after a median follow-up of 68 months; fewer withdrawals and fewer side effects with anastrozole, especially gynaecological problems and vascular events, but arthralgia and fractures were increased.10
Leder and colleagues, 20043Randomised, double-blind, placebo-controlled337 men aged 62 to 74 with screening testosterone below 350 ng/dl3Anastrozole 1 mg daily or 1 mg twice weekly, or placebo, 12 weeks3Total testosterone 343 to 572 ng/dl (daily, n = 12) and 397 to 520 ng/dl (twice weekly, n = 11); estradiol 26 to 17 and 27 to 17 pg/ml; both P < 0.001 against placebo (n = 14).3
Burnett-Bowie and colleagues, 20094Randomised, double-blind, placebo-controlled488 men aged 60 and older with low or borderline testosterone and symptoms of hypogonadism4Anastrozole 1 mg daily or placebo, 1 year4Testosterone 11.2 to 18.2 nmol/L at month 3 (p < 0.0001 against placebo); body composition and strength did not change.4
Burnett-Bowie and colleagues, bone analysis, 20095Randomised, double-blind, placebo-controlled569 men aged 60 and older with borderline or low testosterone and hypogonadal symptoms5Anastrozole 1 mg daily or placebo, 1 year5Spine bone mineral density decreased on anastrozole compared with placebo (P = 0.0014); bone turnover markers were not affected.5
Finkelstein and colleagues, New England Journal of Medicine, 20138Randomised; National Institutes of Health grants and an investigator-initiated grant from Abbott Laboratories8Healthy men aged 20 to 50: 198 without and 202 with anastrozole8Goserelin and testosterone gel; anastrozole 1 mg daily in the second cohort; 16 weeks8With anastrozole, the percentage of body fat increased in all groups.8
Helo and colleagues, 20159Randomised, double-blind comparison with clomiphene926 hypogonadal infertile men with testosterone below 350 ng/dL and normal LH9Clomiphene 25 mg/day or anastrozole 1 mg/day, 12 weeks9Mean testosterone increase 571 (clomiphene) against 408 ng/dL (anastrozole); estradiol decreased on anastrozole.9
Herzog and colleagues, 201012Randomised, double-blind, placebo-controlled1240 men with focal epilepsy, hyposexuality and hypogonadism12Depotestosterone with anastrozole or placebo, 3 months; the anastrozole dose is not given in the PubMed entry12Normalisation of sexual function 72.2% against 47.4%, not statistically significant; estradiol was significantly lower with anastrozole.12
Mauras and colleagues, 20097,13Open-label, no control group; AstraZeneca is the registry's lead sponsor7,1342 boys with gynecomastia, mean age 137Anastrozole 1 mg daily for 6 months7Terminal half-life 46.8 hours; breast area fell approximately 63% from baseline (P = 0.004) in an exploratory analysis.7 The label's placebo-controlled study of 80 boys found no statistically significant difference in its primary efficacy analysis.1

Deeper analysis: ATAC

The US label describes ATAC as a double-blind trial that randomized postmenopausal women with operable breast cancer to anastrozole 1 mg daily, tamoxifen 20 mg daily, or both, for five years or until recurrence, with disease-free survival as the primary endpoint.1 The combination arm was discontinued at a median follow-up of 33 months because it showed no efficacy benefit over tamoxifen alone.1 The ClinicalTrials.gov entry names AstraZeneca as lead sponsor and lists 9358 participants.11 The PubMed entry for the 2010 report by Cuzick and colleagues lists a Breast Cancer Now research centre grant and the ATAC/LATTE investigators, and the PubMed entries for the 2005 and 2010 reports do not state the authors' ties to AstraZeneca or their own limitations.14

At a median follow-up of 120 months, Cuzick and colleagues report a disease-free survival hazard ratio of 0·91 (95% CI 0·83-0·99; p=0·04) in all randomised patients and 0·86 (95% CI 0·78-0·95; p=0·003) in hormone-receptor-positive patients, with little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4).14 The US label reports a hazard ratio of 0.91 (95% CI 0.73 to 1.13) in women who had previous adjuvant chemotherapy.1 Howell and colleagues' 2005 conclusion names anastrozole as the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.10

In the label's safety population, hot flashes were reported by 36% of women on anastrozole and 41% on tamoxifen, musculoskeletal events by 36% and 29%, all fractures by 10% and 7%, hypercholesterolemia by 9% and 3.5%, venous thromboembolic events by 3% and 5%, vaginal bleeding by 5% and 10%, and vaginal discharge by 4% and 13%.1 Ischemic cardiovascular events were 4% on anastrozole and 3% on tamoxifen overall, with no statistical difference, and 17% against 10% in women with pre-existing ischemic heart disease.1 Hot flashes were the most common adverse reaction leading to discontinuation in both groups, with fewer patients on anastrozole discontinuing for it.1 In the 2010 follow-up, fractures during active treatment were 451 on anastrozole and 351 on tamoxifen (OR 1·33, 95% CI 1·15-1·55; p<0·0001) and similar afterwards (110 and 112), and colorectal cancer (66 and 44) and lung cancer (51 and 34) continued to be higher with anastrozole while other cancers overall were 425 and 431.14 Endometrial cancer (6 and 24), melanoma (8 and 19) and ovarian cancer (17 and 28) were lower with anastrozole.14 Treatment-related serious adverse events were 223 on anastrozole and 369 on tamoxifen (OR 0·57, 95% CI 0·48-0·69; p<0·0001) and similar after treatment completion (66 and 78), and no new safety concerns were reported.14

Deeper analysis: trials in older men with low testosterone

Leder and colleagues, Massachusetts General Hospital, Journal of Clinical Endocrinology and Metabolism, 2004, report that bioavailable testosterone rose from 99 to 207 ng/dl on the daily dose and from 115 to 178 ng/dl on the twice-weekly dose (P < 0.001 against placebo for both), and LH rose from 5.1 to 7.9 and from 4.1 to 7.2 U/liter.3 Hematocrit and the scores for the MOS Short-Form Health Survey, the International Index of Erectile Function and the American Urological Association Symptom Index did not change, and prostate-specific antigen rose in the twice-weekly group only, from 1.7 to 2.2 ng/ml (P = 0.031 compared with placebo).3 The authors write that "the physiological consequences of these changes remain to be determined", and the PubMed entry lists a National Center for Research Resources grant, K23-RR16310, as research support.3

In the 88-man trial, Burnett-Bowie and colleagues, Clinical Endocrinology, 2009, report that testosterone declined by month 12 while remaining above baseline and placebo, estradiol fell from 55.8 to 42.2 pmol/L at month 3 and then remained stable, and PSA, BPH symptoms, hematocrit and lipid levels did not change.4 The authors write that these alterations "did not improve body composition or strength", and the PubMed entry lists grants from the National Center for Research Resources and the National Institute on Aging.4 In the bone analysis of 69 men, Burnett-Bowie and colleagues, Journal of Clinical Endocrinology and Metabolism, 2009, report spine bone mineral density falling from 1.121 to 1.102 g/cm² on anastrozole and rising from 1.180 to 1.189 g/cm² on placebo, and conclude that "aromatase inhibition does not improve skeletal health in aging men with low or low normal testosterone levels".5 The PubMed entries for the two Burnett-Bowie reports do not list the authors' limitations.5

Deeper analysis: Finkelstein and colleagues, 2013

Finkelstein and colleagues, Massachusetts General Hospital, New England Journal of Medicine, 2013, gave healthy men aged 20 to 50 goserelin acetate to suppress endogenous testosterone and estradiol, then randomised them to placebo gel or testosterone gel for 16 weeks, and a second cohort of 202 men also received anastrozole 1 mg daily to block the aromatization of testosterone to estrogen.8 The primary outcomes were the percentage of body fat and lean mass.8 With anastrozole, the percentage of body fat increased in all groups, and total-body lean mass decreased in men who received placebo compared with those who received 1.25 g, 2.5 g or 10 g of testosterone daily.8 The authors conclude that "estrogen deficiency primarily accounted for increases in body fat" and that both androgen and estrogen deficiency contributed to the decline in sexual function.8

The paper reports National Institutes of Health grants and an investigator-initiated grant from Abbott Laboratories, names the anastrozole as Arimidex from AstraZeneca and the testosterone gel as AndroGel from Abbott Laboratories, and states that the authors' disclosure forms are available with the full text at NEJM.org.8 Abbott Laboratories provided partial financial support and supplied the testosterone gel at no charge, AstraZeneca provided goserelin and anastrozole at no cost, and the paper states that neither company had a role in the study design, data analysis, data interpretation or manuscript preparation.8 The authors list limitations: the study was limited to 16 weeks, circulating estradiol levels "may not reflect estrogen effects reliably", and acute gonadal steroid deprivation may differ from a gradual decline over years.8 The men were healthy with normal baseline testosterone and received goserelin, so the trial did not test anastrozole in men with low testosterone.8

Helo and colleagues, 2015, compared clomiphene with anastrozole and report that testosterone rose in both groups, the testosterone-to-estradiol ratio rose significantly only with anastrozole, neither group showed significant changes in seminal parameters or patient-reported outcomes, and the authors state "We failed to demonstrate equivalence of CC vs. AZ".9

The app's typical dose range is 0.25 to 1 mg a day, and a dose of 0.25 mg does not appear among the doses in the table below.

Table 5.1Doses reported in studies and on labels8 rows
SourcePeopleDose and length
US label1Postmenopausal women with breast cancer1One 1 mg tablet of anastrozole once a day, until tumor progression in advanced breast cancer and for five years in ATAC1
US label, estradiol studies1Postmenopausal women with advanced breast cancer10.5, 1, 3, 5 and 10 mg daily1
UK summary of product characteristics2Adults including the elderly; in the tolerability statement, healthy male volunteers (single dose) and postmenopausal women with advanced breast cancer (daily dose)2One 1 mg tablet once a day; up to 60 mg in a single dose in the volunteers and up to 10 mg daily in the women were well tolerated2
Leder and colleagues, 2004337 men aged 62 to 7431 mg daily or 1 mg twice weekly, 12 weeks3
Burnett-Bowie and colleagues, 2009488 men aged 60 and older41 mg daily, 1 year4
Finkelstein and colleagues, 20138202 healthy men aged 20 to 50 given goserelin and testosterone gel81 mg daily, 16 weeks8
Helo and colleagues, 2015926 hypogonadal infertile men91 mg/day, 12 weeks9
Mauras and colleagues, 2009; US label gynecomastia study7,142 boys in one study and 80 boys in the other, with gynecomastia7,11 mg daily, 6 months7,1

The US label lists adverse reactions occurring in at least 10% of women taking Arimidex: hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis and lymphedema.1 Serious adverse reactions occurring in fewer than 1 in 10,000 patients are skin reactions such as lesions, ulcers or blisters, allergic reactions with swelling of the face, lips, tongue or throat, and changes in liver function blood tests.1 Its warnings cover ischemic cardiovascular events in women with pre-existing ischemic heart disease, decreases in bone mineral density, increases in total cholesterol and embryo-fetal toxicity.1

In the label's placebo-controlled study of 80 boys with pubertal gynecomastia, treatment-related adverse reactions occurred in 16.3% on anastrozole and 8.1% on placebo, the most frequent being acne (7% and 2.7%) and headache (7% and 0%), and one boy on anastrozole discontinued because of testicular enlargement.1 In the UK summary's study of 52 pubertal boys with growth hormone deficiency given anastrozole 1 mg a day or placebo in combination with growth hormone, only 14 on anastrozole completed 36 months, there was no significant difference from placebo in growth-related parameters, and there was an increased fracture rate and a trend towards reduced bone mineral density on anastrozole compared with placebo, and the summary states that the number of children treated was too limited to draw reliable conclusions on safety.2 In adult men, the trials above reported a spine bone mineral density decrease compared with placebo over 1 year and a prostate-specific antigen rise in the twice-weekly group only over 12 weeks.5,3

7

Bloodwork and markers

The app lists total testosterone, free testosterone, estradiol, LH and FSH as markers to monitor for anastrozole. Helo and colleagues assayed total testosterone, free testosterone, estradiol, LH, FSH and sex hormone binding globulin at baseline, 6 and 12 weeks.9 Mauras and colleagues report that testosterone-to-estradiol ratios increased significantly with a concomitant increase in LH and FSH concentrations, which they describe as indicating aromatase blockade.7

8

Regulatory and anti-doping status

The US label for Arimidex lists ANI Pharmaceuticals, Inc. for adverse reaction reports and has breast cancer indications in postmenopausal women.1 The US label states that efficacy has not been demonstrated for pubertal boys of adolescent age with gynecomastia or girls with McCune-Albright Syndrome and progressive precocious puberty, and the UK summary states that Arimidex is not recommended for use in children and adolescents due to insufficient data on safety and efficacy.1,2

The WADA 2026 Prohibited List, in effect from 1 January 2026, lists aromatase inhibitors in class S4.1, with anastrozole among the examples.6 Class S4 is prohibited at all times, in and out of competition, and substances in classes S4.1 and S4.2 are Specified Substances.6

9

Storage and handling

Sources in this part

  1. 1ANI Pharmaceuticals, 2026

The US label states that Arimidex 1 mg tablets are supplied in bottles of 30 tablets and are stored at controlled room temperature, 20 to 25°C (68 to 77°F).1

The US label and the UK summary of product characteristics give no percentage for oral bioavailability, so the app's 95% is not stated in either.1,2 The US label's pharmacokinetic section states that anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer, and its pediatric section gives a time to maximum concentration of 1 hour and a terminal elimination half-life of 46.8 hours.1 For adjuvant treatment of early breast cancer in postmenopausal women, the label states that the optimal duration of therapy is unknown.1 The men's trials above lasted 12 to 16 weeks except the two Burnett-Bowie reports of 1 year of treatment, and the authors of the 2004 Leder trial state that the physiological consequences of the hormone changes remain to be determined.3,4,8 The PubMed entries for the two Burnett-Bowie reports do not state whether the 69 men in the bone analysis were among the 88 men in the other report.4,5 The breast size reduction reported by Mauras and colleagues came from an exploratory analysis in an open-label study, and the authors state that it "deserves further study".7

What is the half-life of anastrozole?

The US label gives a mean elimination half-life of anastrozole of 50 hours, and the UK summary of product characteristics gives 40 to 50 hours.1,2 The app uses about 2 days (48 hours), and in 42 boys with gynecomastia the terminal half-life was 46.8 hours.7

Is anastrozole banned by WADA?

Yes, the WADA 2026 Prohibited List names anastrozole among the aromatase inhibitors in class S4.1, which is prohibited at all times, in and out of competition.6

How long does anastrozole take to reach steady state?

The US label states that plasma concentrations approach steady-state levels at about 7 days of once daily dosing, at levels approximately 3- to 4-fold higher than after a single dose.1

What is the bioavailability of anastrozole?

The US label gives no percentage and states that orally administered anastrozole is well absorbed into the systemic circulation.1 The app lists about 95%, and the UK summary of product characteristics gives no percentage either.2

What is Arimidex used for?

The US label lists adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown advanced breast cancer, and treatment of advanced breast cancer in postmenopausal women after tamoxifen.1

How much does anastrozole lower estradiol?

In postmenopausal women with advanced breast cancer, the US label reports that 1 mg reduced estradiol by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing.1 In 12 men given 1 mg daily for 12 weeks in a trial of 37 men aged 62 to 74 with low or borderline-low testosterone, Leder and colleagues found mean estradiol fell from 26 to 17 pg/ml.3

Does anastrozole raise testosterone in men?

In randomised trials in older men with low or borderline-low testosterone, anastrozole 1 mg daily raised testosterone, from 343 to 572 ng/dl over 12 weeks in Leder and colleagues' trial and from 11.2 to 18.2 nmol/L at month 3 in Burnett-Bowie and colleagues' trial.3,4 In the 1-year trial testosterone declined by month 12 while remaining above baseline and placebo, body composition and strength did not change, and a bone analysis found spine bone mineral density fell compared with placebo.4,5

What are the side effects of anastrozole in trials?

In the ATAC trial, the label reports hot flashes in 36% of women on anastrozole against 41% on tamoxifen, musculoskeletal events in 36% against 29%, all fractures in 10% against 7%, and hypercholesterolemia in 9% against 3.5%.1 In older men, a prostate-specific antigen rise in the twice-weekly group only and a spine bone mineral density decrease compared with placebo were reported.3,5

13

References

  1. ANI Pharmaceuticals, Inc. Arimidex (anastrozole) tablet, prescribing information. DailyMed, US National Library of Medicine, 2026. DailyMed label
  2. AstraZeneca UK Limited. Arimidex 1 mg film-coated tablets, summary of product characteristics. electronic medicines compendium, 2026. emc SmPC
  3. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004. PMID 15001605
  4. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2009. PMID 18616708
  5. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009. PMID 19820017
  6. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA Prohibited List 2026
  7. Mauras N, Bishop K, Merinbaum D, Emeribe U, Agbo F, Lowe E. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab 2009. PMID 19470631
  8. Finkelstein JS, Lee H, Burnett-Bowie SM, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013. PMC4142768
  9. Helo S, Ellen J, Mechlin C, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med 2015. PMID 26176805
  10. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005. PMID 15639680
  11. AstraZeneca. ATAC - Arimidex, Tamoxifen Alone or in Combination. ClinicalTrials.gov, NCT00849030. NCT00849030
  12. Herzog AG, Farina EL, Drislane FW, et al. A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism. Epilepsy Behav 2010. PMID 20096638
  13. AstraZeneca. Open Label Arimidex in Gynecomastia. ClinicalTrials.gov, NCT00241436. NCT00241436
  14. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010. PMID 21087898